Current use of CAR T cells to treat multiple myeloma

Anti -B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies currently approved by the US Food and Drug Administration (FDA) have dra mat i cally improved clin i cal out comes for patients with heavily pretreated multiple myeloma who have disease refractory to conventional proteasome inhibitors, immunomodulatory drugs, and anti- CD38 mono clo nal antibodies. However, despite this prog ress, mul ti ple mye loma remains an incur able hema to logic malig nancy. In this review, we dis cuss prac ti cal con sid er ations for cur rently FDA approved CAR T- cell ther a pies, including newer data eval u at ing those agents in ear lier lines of ther apy. We also dis cuss con sid er ations for patients fol low ing relapse from anti-BCMA CAR T-cell therapy, which currently represents an unmet clinical need.